Journal Watch · Frontiers in Immunology · 2026
VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.
In the population with intermediate NAb levels, the 2- to 5-day depletion in anti-AAV3B NAbs supports VTX-PID as a promising pretreatment approach to open a window of opportunity of up to 5 days, broadening eligibility for systemic AAV-based gene therapies.
TL;DR
In the population with intermediate NAb levels, the 2- to 5-day depletion in anti-AAV3B NAbs supports VTX-PID as a promising pretreatment approach to open a window of opportunity of up to 5 days, broadening eligibility for systemic AAV-based gene therapies.
Key findings
- The safety profile was manageable, with few temporary inflammatory events and self-resolving liver enzyme elevations.
- VTX-PID 0.3 mg/kg was identified as the appropriate dose based on its safety and efficacy profile.
- In the population with intermediate NAb levels, the 2- to 5-day depletion in anti-AAV3B NAbs supports VTX-PID as a promising pretreatment approach to open a window of opportunity of up to 5 days, broadening eligibility for systemic AAV-based gene therapies.
What they did
Key secondary endpoints included levels of anti-AAV3B NAbs and total antibodies (TAbs).<h4>Results</h4>VTX-PID resulted in substantial reductions in total IgG, undigested IgG, anti-AAV3B TAb and NAb levels across all doses, followed by gradual full recovery, with effects being sustained longer (2-5 days) at the highest doses. All participants with intermediate NAb levels achieved durable noninhibitory NAb levels (titer ≤1:5), while those with high NAb levels showed reduction but did not reach the noninhibitory level. Most participants experienced VTX-PID-related treatment-emergent adverse events, primarily musculoskeletal complaints of predominately mild to moderate intensity and fully reversible. Transient mild to moderate infusion-associated reactions occurred in four participants, and reversible liver function test elevations in three.<h4>Discussion</h4>VTX-PID effectively depleted anti-AAV3B NAbs, with a dose-dependent effect in magnitude and duration.
Full abstract (original)
Background: <h4>Introduction</h4>Pre-existing anti-adeno-associated virus (AAV) neutralizing antibodies (NAbs) can impair AAV-mediated gene delivery. VTX-PID (imlifidase) is a streptococcal protease that specifically cleaves immunoglobulin G (IgG) antibodies. NAVIgATE was a first-in-human study of VTX-PID.<h4>Methods</h4>This double-blind controlled study (EUCT number: 2023-503892-83-00) randomized 35 healthy men, stratified by baseline anti-AAV3B NAb levels (intermediate [≤ 1:45] or high [>1:45]) to receive ascending VTX-PID doses (0.075-0.6 mg/kg) or placebo. The primary endpoint was safety.
What they did: Key secondary endpoints included levels of anti-AAV3B NAbs and total antibodies (TAbs).<h4>Results</h4>VTX-PID resulted in substantial reductions in total IgG, undigested IgG, anti-AAV3B TAb and NAb levels across all doses, followed by gradual full recovery, with effects being sustained longer (2-5 days) at the highest doses. All participants with intermediate NAb levels achieved durable noninhibitory NAb levels (titer ≤1:5), while those with high NAb levels showed reduction but did not reach the noninhibitory level. Most participants experienced VTX-PID-related treatment-emergent adverse events, primarily musculoskeletal complaints of predominately mild to moderate intensity and fully reversible. Transient mild to moderate infusion-associated reactions occurred in four participants, and reversible liver function test elevations in three.<h4>Discussion</h4>VTX-PID effectively depleted anti-AAV3B NAbs, with a dose-dependent effect in magnitude and duration.
Results & conclusions: The safety profile was manageable, with few temporary inflammatory events and self-resolving liver enzyme elevations. VTX-PID 0.3 mg/kg was identified as the appropriate dose based on its safety and efficacy profile. In the population with intermediate NAb levels, the 2- to 5-day depletion in anti-AAV3B NAbs supports VTX-PID as a promising pretreatment approach to open a window of opportunity of up to 5 days, broadening eligibility for systemic AAV-based gene therapies.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1824802 · PubMed 42245647.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery, gene therapy — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery · gene therapy
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
In the population with intermediate NAb levels, the 2- to 5-day depletion in anti-AAV3B NAbs supports VTX-PID as a promising pretreatment approach to open a window of opportunity of up to 5 days, broadening eligibility for systemic AAV-based gene therapies.
What type of study is this?
It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Key secondary endpoints included levels of anti-AAV3B NAbs and total antibodies (TAbs).<h4>Results</h4>VTX-PID resulted in substantial reductions in total IgG, undigested IgG, anti-AAV3B TAb and NAb levels across all doses, followed by gradual full recovery, with effects being sustained longer (2-5 days) at the highest doses.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1824802. PubMed ID: 42245647. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/vtx-pid-as-a-novel-recombinant-immunoglobulin-g-degrading-enzyme-ides-fo-824802/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides